

# ASX ANNOUNCEMENT

31 May 2023

## DurAVR™ THV Maintains Exceptional Results in New Patient Cohort

**BRISBANE, Australia** and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) announces DurAVR™ THV delivers exceptional haemodynamic outcomes in a third patient cohort, comprising seven First-in-Human Study participants and one compassionate case, further validating results previously reported.

### Preliminary Results:

- 7 patients were enrolled; the DurAVR™ THV achieved 100% procedural success with no device-related complications.
- Study participants' baseline characteristics: mean age 74.86 years, gender 86% female, mean annulus diameter 22.33 mm, New York Heart Class II and III – 71% and 29%, respectively (classifying the extent of heart failure).
- Transesophageal echocardiogram (TEE) taken 48 hours post-procedure showed favourable results – average Effective Orifice Area (EOA, cm<sup>2</sup>) increased from 0.76 to 2.11, a 178% increase from baseline – an indicator of improved long-term survival and exercise capacity.
- Mean Pressure Gradients (MPG, mmHg) decreased by 84% from a baseline of 53.34 to 8.66 post-procedure (48 hours).
- An additional compassionate case with complex bicuspid aortic valve morphology and a left ventricular ejection fraction of 33% was also successfully treated; EOA increased 250% from a baseline of 0.60 to 2.10 48-hours post-procedure, while MPG decreased from a baseline of 79.00 to 19.00 mmHg post-procedure – a 76% improvement.

### Anteris Technologies Chief Executive Officer Wayne Paterson said:

"We have now treated 21 patients, all of whom have had outstanding results. This recent cohort of patients further validates the exceptional clinical characteristics of DurAVR™ THV and the performance of our novel first-in-class biomimetic design. I would like to acknowledge the patients and physicians who are involved in this study and thank them for their participation".

### Anteris Technologies Chief Medical Officer Chris Meduri, MD, added:

"We continue to see encouraging clinical results and excellent patient outcomes, further building upon the body of evidence that supports the use of DurAVR™ THV in patients with aortic stenosis. Furthermore, the restoration of normal flow, which is a function of the biomimetic design, has not been observed with existing therapies and will have significant clinical benefits both in the short and longer term for patients."

**ENDS**

#### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

### **Authorisation and Additional information**

This announcement was authorised by the Board of Directors.

### **For more information:**

#### **Investor contact**

Deanne Curry

GRACosway

E: [investors@anteristech.com](mailto:investors@anteristech.com)

M: +61 414 388 997

#### **Media contact**

Nick Howe

GRACosway

[nhowe@gracosway.com.au](mailto:nhowe@gracosway.com.au)

M: +61 407 183 221

[www.anteristech.com](http://www.anteristech.com)

Twitter: [@AnterisTech](https://twitter.com/AnterisTech)

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>